Category: Press Releases

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are

The threat modeling platform launches ‘Jeff: AI Assistant’, a world first in terms of creating threat models through language and images. The new feature is the latest development in IriusRisk’s expansion into AI, a move which helped to deliver more than 50% Annual Recurring Revenue (ARR) growth last year. ATLANTA,

Quantexa earned a top ranking in the RiskTech100® 2025 Report, highlighting its strength and innovation in the expanding risk technology and compliance market LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) — Quantexa, a leading provider of Decision Intelligence solutions for public and private sectors, today announced it has received recognition in

Leil Storage for Africa TALLINN, Estonia, Oct. 21, 2024 (GLOBE NEWSWIRE) — In alignment with Africa Human Rights Day, Leil Storage announces the expansion of its Green Storage Initiative, an endeavor set to revolutionize file storage across Africa. This initiative underscores commitment to sustainability and affordability, promising a profound impact

Leil Storage for Africa TALLINN, Estonia, Oct. 21, 2024 (GLOBE NEWSWIRE) — In alignment with Africa Human Rights Day, Leil Storage announces the expansion of its Green Storage Initiative, an endeavor set to revolutionize file storage across Africa. This initiative underscores commitment to sustainability and affordability, promising a profound impact

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases Cureverse receives undisclosed upfront payments and is eligible for future milestone-dependent payments and royalties, while retaining rights to commercialize